Iovance Files for $89.7M Mixed Shelf Offering
Summary
Iovance Biotherapeutics has filed for a mixed shelf offering, specifically a prospectus supplement for an at-the-market (ATM) offering of up to $89.7 million in common stock. This follows shareholder approval in April to increase authorized common stock and previous ATM capital raises, as noted in their Q1 10-Q. The offering represents a moderate potential for dilution for existing shareholders, providing the company with additional capital for its operations.
At the time of this announcement, IOVA was trading at $3.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $1.66 to $5.63. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.